Inventiva S.A.
IVA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for IVA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IVA
Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing lanifibranor for the treatment of MASH (metabolic dysfunction-associated steatohepatitis), with no approved products and a history of pipeline prioritization and restructuring.
Key risk: Going concern uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2025.
Tracking 1 clinical trial · 1 catalyst for Inventiva S.A..
Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing lanifibranor for the treatment of MASH (metabolic dysfunction-associated steatohepatitis), with no approved products and a history of pipeline prioritization and restructuring.
- Inventiva is a clinical-stage company with no approved products and no historical product revenues, making it difficult to assess future prospects [sec · filed 2026-04-08].
- As of June 30, 2025, the company had cash & equivalents of $14.2M, shareholders' equity of -$32.0M, and total debt of $129.4M [sec].
- The 2025 Pipeline Prioritization Plan reduced the workforce by slightly more than 50% and discontinued all pre-clinical programs, including YAP-TEAD and NR4A1, to focus exclusively on lanifibranor [sec · filed 2026-04-08].
- In December 2025, Inventiva sold rights to odiparcil to Biossil for $600,000 upfront, with potential milestone payments and royalties [sec · filed 2026-04-08].
- The company's ability to continue as a going concern is in doubt, with substantial doubt raised regarding its ability to continue operations [sec · filed 2025-04-15].
What works
- Inventiva has a focused pipeline with lanifibranor as its lead candidate for MASH, a large unmet medical need, and has completed Phase 2b trials with results announced in June 2023 [sec · filed 2026-04-08].
- The company has entered into partnership agreements, such as with CTTQ and Hepalys, which could provide milestone payments and support development [sec · filed 2025-04-15].
- The asset sale of odiparcil to Biossil provides a potential revenue stream through milestones and royalties, reducing some financial risk [sec · filed 2026-04-08].
What to weigh
- Inventiva has no approved products and has never generated revenue from product sales, with its business dependent on the successful development of lanifibranor [sec · filed 2026-04-08].
- The company has a high debt burden of $129.4M and negative shareholders' equity of -$32.0M as of June 30, 2025, raising substantial doubt about its ability to continue as a going concern [sec] [sec · filed 2025-04-15].
- The 2025 pipeline prioritization led to a workforce reduction of over 50% and discontinuation of all pre-clinical programs, indicating significant operational restructuring [sec · filed 2026-04-08].
- Clinical development risks include potential delays, side effects, and regulatory hurdles that could harm commercial prospects [sec · filed 2026-04-08].
From the filings
Quoted directly from source documents.
Inventiva is a clinical-stage company with no approved products and no historical product revenues.
“We are a clinical-stage company with no approved products and no historical product revenues, which makes it difficult to assess”
SEC filings · April 8, 2026
The 2025 Pipeline Prioritization Plan reduced workforce by over 50% and discontinued pre-clinical programs.
“The 2025 Pipeline Prioritization Plan, which was substantially completed by the end of 2025, reduced our overall workforce by slightly more than 50%.”
SEC filings · April 8, 2026
Inventiva sold odiparcil assets to Biossil for $600,000 upfront with potential milestones.
“we entered into an asset purchase agreement with Biossil pursuant to which we sold and assigned all rights in assets relating to odiparcil to Biossil for an upfront payment of $600,000”
SEC filings · April 8, 2026
Substantial doubt exists about the company's ability to continue as a going concern.
“These factors raise substantial doubt regarding our ability to continue as a going concern.”
SEC filings · April 15, 2025
Catalyst timeline
- 2027-09-30 · Phase3_Topline — Topline results from a randomized, double-blind, placebo-controlled Phase 3 study evaluating lanifibranor for MASH.
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue as a going concern due to negative equity and high debt [sec · filed 2025-04-15].
- Dependence on lanifibranor — Business depends heavily on successful development and approval of lanifibranor; no other pipeline candidates [sec · filed 2026-04-08].
- Clinical trial risks — Potential delays, side effects, or regulatory issues could harm development and commercial prospects [sec · filed 2026-04-08].
- Debt and liquidity — Total debt of $129.4M and cash of $14.2M as of June 30, 2025, may require refinancing or asset sales [sec].
What to watch
- Phase 3 topline results for lanifibranor expected in 2027-09-30 [catalyst].
- Ability to secure additional financing or partnerships to fund operations and debt obligations [sec · filed 2026-04-08].
- Progress on milestone payments from Biossil for odiparcil [sec · filed 2026-04-08].
- Regulatory interactions and potential approval decisions for lanifibranor [sec · filed 2026-04-08].
Sources: SEC filings · Generated August 28, 2026 · How we verify sources →
Run Inventiva S.A. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Inventiva S.A. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Cash runway data unavailable
OCF -$86M
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~396d
No insider transactions in the last 180 days
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
62
Total value held
$227.2M
| Holder | Shares | Value |
|---|---|---|
| samsara biocapital, llc | 5,194,805 | $28.8M |
| caligan partners lp | 4,974,906 | $27.6M |
| millennium management llc | 2,987,613 | $16.6M |
| franklin resources inc | 2,461,565 | $13.7M |
| adar1 capital management, llc | 2,174,398 | $12.1M |
| polar capital holdings plc | 2,132,138 | $11.8M |
| andera partners | 1,818,181 | $10.1M |
| yu fan | 1,500,000 | $8.3M |
| boothbay fund management, llc | 1,470,407 | $8.2M |
| nea management company, llc | 1,462,586 | $8.0M |
Showing top 10 of 62 institutional holders of Inventiva S.A.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 0.2%
- Days to cover
- 1.0
- Shares short
- 438,164
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IVA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Inventiva S.A.?
Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing lanifibranor for the treatment of MASH (metabolic dysfunction-associated steatohepatitis), with no approved products and a history of pipeline prioritization and restructuring.
What is Inventiva S.A.'s next catalyst?
Inventiva S.A.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Efficacy and S" — expected September 30, 2027.
Who is the CEO of Inventiva S.A.?
Mr. Andrew Obenshain is the chief executive officer of Inventiva S.A. (IVA).
Where is Inventiva S.A. headquartered?
Inventiva S.A. (IVA) is headquartered in Daix, France.
What therapeutic areas does Inventiva S.A. focus on?
Inventiva S.A. develops therapies across Infectious Disease, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.